News und Analysen
This High-Yield Dividend Stock Has Nearly Tripled the S&P 500's Performance Over the Past Year. Should Investors Continue to Buy It?
The U.S. stock market, characterized by the S&P 500, has been on a tear since the artificial intelligence (AI) revolution began in early 2023. The index has risen approximately 24% over the past
3 Magnificent Growth Stocks to Buy Right Now
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value. But which stocks are likely to deliver growth over the
Is Merck Stock a Buy?
It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates with
3 Magnificent Dividend Growth Stocks With Yields Above 5% to Buy Now and Hold at Least a Decade
There are many ways to make money on Wall Street, but some methods are a lot more reliable than others. Whether you're looking for a way to raise the stream of passive income your portfolio produces
Why Exelixis Stock Trounced the Market on Thursday
Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to
Is Medtronic Stock a Buy?
Medical device manufacturer Medtronic (NYSE: MDT) is a healthcare industry stalwart. The company, based in the U.S. and Ireland, is one of the largest in its segment, developing and selling a
Why UnitedHealth Stock Is Down Today
The U.S. Department of Justice has reportedly launched an investigation into UnitedHealth Group's (NYSE: UNH) Medicare billing practices.
Investors were shaken by the report, sending UnitedHealth
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Looking for a good area in which to invest? Consider the healthcare sector. People must have healthcare. And with aging populations, the demand for healthcare products and services should grow
Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Dynavax Technologies (NASDAQ: DVAX)Q4 2024 Earnings CallFeb 20, 2025, 4:30 p.m. ET
Operator
Source Fool.com
Trupanion: A Solid Investment in the Growing Pet Insurance Market?
In this episode of the Motley Fool Scoreboard, analysts evaluate Trupanion (NASDAQ: TRUP) and its potential as a pet insurance leader. With a solid track record and a growing market, is Trupanion a
Ardelyx Tops Estimates as Sales Surge
Ardelyx (NASDAQ:ARDX), a biopharmaceutical company specializing in innovative treatments for gastrointestinal and kidney diseases, released its fourth-quarter earnings report on Feb. 20. The release
Why I Decided to Buy AMD Stock Despite the Bad Sentiment
In this video, I will cover the recent updates about Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.
*Stock
The Smartest Dividend Stock to Buy With $1,000 Right Now
While many investors focus on a company's stock price, dividends can often be unsung heroes when it comes to making money. Dividend stocks may not be as sexy as growth stocks or get much of the same
Better Artificial Intelligence Stock: Nvidia vs. AMD
Discrete GPUs were initially designed for use in video games and professional graphics applications, but they've now become the backbone of data centers that use them to process all sorts of
Trupanion Posts Revenue Beat, EPS Miss
Trupanion (NASDAQ:TRUP), a leader in pet medical insurance, released its Q4 2024 earnings on February 19, 2025. The company delivered mixed results, with earnings per share (EPS) at $0.04, missing
Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2024 Earnings CallFeb 19, 2025, 8:00 a.m. ET
Operator
Source Fool.com
Medtronic (MDT) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.
Medtronic (NYSE: MDT)Q3 2025 Earnings CallFeb 18, 2025, 8:00 a.m. ET
Ryan Weispfenning -- Vice President and Head, Investor Relations
Source Fool.com
Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q4 2024 Earnings CallFeb 18, 2025, 8:00 a.m. ET
Operator
Source Fool.com
This Company Just Initiated a Quarterly Dividend: Time to Buy?
Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The company's results were strong, coming in ahead of analyst estimates
Axsome Therapeutics Revenue Surges 66%
Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales
3 Things You Need to Know If You Buy Pfizer Today
Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent times. Thanks to its coronavirus treatment and vaccine, the pharma giant
Prediction: This Long-Awaited Catalyst Could Drive Rivian Stock Higher in 2025
It's a reasonable concern for Rivian Automotive (NASDAQ: RIVN) investors that the company has no real visible catalysts in 2025. The R2 won't launch until 2026, Rivian already inked a big deal with
3 Stocks That Could Trounce the Market in 2025
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Three
EQS-News: Sartorius releases Annual Report for 2024
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
It's only mid-February, but as of this writing biotech company Axsome Therapeutics (NASDAQ: AXSM) is up by 55% year to date. Substantial stock-market gains over short periods aren't that rare in the